NEW YORK – July 16, 2018 – The Cardiovascular Research Foundation (CRF) is pleased to announce that its premier translational research facility, the CRF Skirball Center for Innovation (SCI), is partnering with Siemens Healthineers to advance their imaging capabilities for structural heart disease research. SCI is dedicated to guiding early ideas and innovations in cardiology through comprehensive preclinical research programs to introduce practical clinical therapies to patients. As part of this collaboration, SCI will now offer a Siemens Healthineers SOMATOM Definition Flash CT scanner, which will help expand SCI’s research capabilities and maximize efficiencies for its sponsors.

“We are very excited to partner on this program with Siemens Healthineers to offer improved CT scanning for use in our structural heart disease research initiatives, allowing SCI to become a true hub of innovation in this area,” said Juan F. Granada, MD, President and Chief Executive Officer of the Cardiovascular Research Foundation. “It will play a significant role in the conduct of our medical device studies and foster the development of new treatments for heart disease.”

“Not only will this new CT scanner allow us to pre-screen test subjects and reduce device-anatomy size discrepancies, but it will also help us identify factors that may impact a procedure,” said Athanasios Peppas, MS, Director of Operations at the CRF Skirball Center for Innovation (SCI). “In addition, it will help us to perform follow-up imaging to evaluate device performance, thrombosis, and tissue interaction.”

“When testing new devices or treatments, the new CT scanner will help us bridge therapies from the preclinical to clinical setting by enhancing our understanding of the device-tissue interaction. In addition, we will be able to incorporate fusion imaging protocols and improve the procedural planning structural heart procedures,” added Torsten P. Vahl, MD, Interventional Research Associate at SCI. Dr. Vahl is the Director of Experimental & Translational Research as well as an attending physician at the Structural Heart & Valve Center and the Center for Interventional Vascular Therapy at NewYork-Presbyterian/Columbia University Irving Medical Center.

“Siemens Healthineers is excited to support the translational research that SCI is focused on, especially in the rapidly growing field of structural heart. Our ability to help advance medical device innovation and understand the imaging requirements of these novel devices will lead ultimately to better patient care and improved clinical outcomes,” said Anthony Medigo, Vice President of Cardiology-Advanced Therapies, Siemens Healthineers North America.

The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer's unique setting. Because there is no "typical" hospital or laboratory and many variables exist (e.g., hospital size, samples mix, case mix, level of IT and/or automation adoption) there can be no guarantee that other customers will achieve the same results.

WHAT & WHO:

The Cardiovascular Research Foundation (CRF) will hold a free seminar, “Healthy Aging: What Women Need to Know About Heart Health at Every Age,” on Thursday, June 14, 2018 in New York City. The seminar, part of a series of Mini-Med School seminars conducted by the CRF Women’s Heart Health Initiative, will focus on providing women with practical ways to keep their heart healthy at all stages of life. Attendees will learn about lifestyle changes, risk factors, and treatment options for coronary artery disease and aortic stenosis, two conditions that develop as you age.

The program will include the following presentations from renowned experts in the field as well as a Q&A session in which attendees will be able to ask questions:

The Early Years: 10 Ways to Defy Heart Disease

Nisha Jhalani, MD

Director, CRF Women’s Heart Health Initiative

Director, Clinical and Educational Services, CIVT

NewYork-Presbyterian/Columbia University Irving Medical Center

Middle-Age: The Signs and Symptoms You Shouldn’t Ignore

Harmony Reynolds, MD

Associate Professor of Medicine, NYU School of Medicine

Director, Soter Center for Women’s Cardiovascular Research

Associate Director, Cardiovascular Clinical Research Center

NYU Langone Health

Seniors: What You Need to Know About Aortic Stenosis

Susheel Kodali, MD

Director, Structural Heart & Valve Center

NewYork-Presbyterian/Columbia University Medical Center

Assistant Professor of Medicine, Columbia University Irving Medical Center

Patient Perspectives
(Q&A and Panel Discussion)

WHY:

Despite prevention efforts and advances in treatments, heart disease remains the number one cause of death for women in the United States. Because heart disease becomes more common as you age, CRF recognizes the importance of educating the public about ways to keep their heart healthy at all stages of life through risk factor management and medical treatment.

WHEN:

Thursday, June 14, 2018

5:30 PM – 7:00 PM

WHERE:

Cardiovascular Research Foundation

1700 Broadway, 9th Floor

New York, NY 10019

HOW TO REGISTER:

To register, visit: http://www.crf.org/whhi/upcoming-events/healthy-aging.

CRF Meeting Covering the Latest in Transcatheter Valve Therapies and LAA and PFO Closure Will Take Place June 20-23 in Chicago

WHAT:

The Cardiovascular Research Foundation (CRF) has announced that the Structural Heart Disease Summit 2018 will feature three studies which will be presented as Late-Breaking Science on Friday, June 22nd in the Sheraton Chicago Ballroom IV- VII from 2:45 PM – 3:30 PM. They include the following studies:

Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device: The SAFE MANTA Study

David A. Wood

Early Commercial Experience Using the PORTICO Transcatheter Aortic Valve: 30-Day Outcomes in 973 Patients Enrolled in the Portico I Study (Cohort A)

Francesco Maisano

Early Clinical Experience With Hybrid Transcatheter Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure

Patrick Klein

New this year, Transcatheter Valve Therapies (TVT) 2018, featuring practical clinical workshops, innovation sessions, and live case demonstrations, is the first part of a comprehensive congress called The Structural Heart Disease Summit. It will be followed by a live case demonstration course on LAA and PFO Closure. TVT 2018 is a practical three-day course featuring the latest research and state-of-the-art techniques for transcatheter aortic and mitral valve therapies. For more than 10 years, TVT has provided healthcare professionals with the latest advances, tools, and techniques for the treatment of valvular heart disease using nonsurgical procedures. LAA and PFO Closure 2018 will provide cardiologists and other healthcare providers with the latest information on the technologies, indications, and outcomes of left atrial appendage (LAA) and patent foramen ovale (PFO) closure to prevent cardioembolic stroke. Live cases will be performed by experts in the field to demonstrate firsthand basic and advanced techniques of LAA and PFO closure.

The agenda for both courses are now available online:

TVT Agenda: http://www.crf.org/tvt/agenda

LAA/PFO Agenda: http://www.crf.org/laa/agenda

The Structural Heart Disease Summit will also feature Interactive Training Workshops where clinicians and members of the Heart Team can learn new skills they can apply immediately to their practice. Workshop topics include Trans-septal Puncture, LAA and PFO Closure, Advanced TAVR Training, and Basic and Advanced Mitral Repair. Additional information can be found online at: http://www.crf.org/structural-heart-disease-summit/training-workshops/overview.

WHY:

Valvular heart disease affects a large number of people who require diagnostic procedures and long-term management. Many patients have no symptoms, but for others, if not treated, advanced heart valve disease can lead to heart failure, stroke, blood clots, or death due to sudden cardiac arrest. Traditionally, valvular heart disease has been treated with surgical repair or replacement. Over the last several years, there have been important advances in concepts, tools, techniques, and patient selection using nonsurgical procedures. Transcatheter valve intervention offers the potential to reduce the procedural morbidity, mortality, and costs of surgical valve replacement or repair while accelerating patient recovery.

WHEN:         

June 20-23, 2018

WHERE:

Sheraton Grand Chicago

301 East North Water Street

Chicago, IL 60611

HOW TO REGISTER:

Media may apply for registration by emailing .

 

CRF Meeting Covering the Latest in Transcatheter Valve Therapies and LAA and PFO Closure Will Take Place June 20-23 in Chicago

WHAT:

New this year, Transcatheter Valve Therapies (TVT) 2018, featuring practical clinical workshops, innovation sessions, and live case demonstrations, is the first part of a comprehensive congress called The Structural Heart Disease Summit. It will be followed by a live case demonstration course on LAA and PFO Closure.

TVT 2018 is a practical three-day course featuring the latest research and state-of-the-art techniques for transcatheter aortic and mitral valve therapies. For more than 10 years, TVT has provided healthcare professionals with the latest advances, tools, and techniques for the treatment of valvular heart disease using nonsurgical procedures. LAA and PFO Closure 2018 will provide cardiologists and other healthcare providers with the latest information on the technologies, indications, and outcomes of left atrial appendage (LAA) and patent foramen ovale (PFO) closure to prevent cardioembolic stroke. Live cases will be performed by experts in the field to demonstrate firsthand basic and advanced techniques of LAA and PFO closure.

The agenda for both courses are now available online:

TVT Agenda: http://www.crf.org/tvt/agenda

LAA/PFO Agenda: http://www.crf.org/laa/agenda

Some of the noteworthy topics include:

  • TAVR and SAVR Therapy: Reconciling Recent Society Guidelines with Clinical Practice Trends
  • Multisociety Appropriate Use Criteria for the Treatment of Patients with Severe Aortic Stenosis
  • Cerebral Embolic Protection Devices for Stroke Prevention
  • Cost-effectiveness and Stroke Incidence after TAVR and SAVR
  • Novel Alternative Vascular Access for TAVR
  • TAVR Access and Underserved Populations
  • Updates from Ongoing Clinical Trials in Patients with “Low-Risk” Aortic Stenosis
  • Measuring the Patient's Perspective: Quality of Life After TAVR
  • Valve Leaflet Thrombosis and TAVR Durability
  • Cardioembolic Stroke and LAA/PFO Closure Overview and Imaging
  • Pharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO
  • Establishing and Growing an Integrated LAA/PFO Closure Program for Cardioembolic Stroke Prevention

The Structural Heart Disease Summit will also feature Interactive Training Workshops where clinicians and members of the Heart Team can learn new skills they can apply immediately to their practice. Workshop topics include Trans-septal Puncture, LAA and PFO Closure, Advanced TAVR Training, and Basic and Advanced Mitral Repair. Additional information can be found online at: http://www.crf.org/structural-heart-disease-summit/training-workshops/overview.

WHY:

Valvular heart disease affects a large number of people who require diagnostic procedures and long-term management. Many patients have no symptoms, but for others, if not treated, advanced heart valve disease can lead to heart failure, stroke, blood clots, or death due to sudden cardiac arrest. Traditionally, valvular heart disease has been treated with surgical repair or replacement. Over the last several years, there have been important advances in concepts, tools, techniques, and patient selection using nonsurgical procedures. Transcatheter valve intervention offers the potential to reduce the procedural morbidity, mortality, and costs of surgical valve replacement or repair while accelerating patient recovery.

WHEN:         

June 20-23, 2018

WHERE:

Sheraton Grand Chicago

301 East North Water Street

Chicago, IL 60611

WHO:

The course directors for TVT 2018 are:

Martin B. Leon, MD

NewYork-Presbyterian/Columbia University Irving Medical Center

Francesco Maisano, MD

UniversitätsSpital Zürich

Nicolo Piazza, MD, PhD

McGill University Health Center

Mark Reisman, MD

University of Washington Medical Center/Regional Heart Center

Gregg W. Stone, MD

NewYork-Presbyterian/Columbia University Irving Medical Center

John G. Webb, MD

St. Paul's Hospital

 

The course directors for LAA/PFO Closure 2018 are:

John D. Carroll, MD

University of Colorado, Denver

Saibal Kar, MD

Cedars-Sinai Medical Center

Vivek Y. Reddy, MD

Mount Sinai Medical Center

Mark Reisman, MD

University of Washington Medical Center/Regional Heart Center

Josep Rodés-Cabau, MD

Quebec Heart and Lung Institute/Laval University

Horst Sievert, MD

CardioVascular Center Frankfurt CVC

Gregg W. Stone, MD

NewYork-Presbyterian/Columbia University Irving Medical Center

HOW TO REGISTER:

Media may apply for registration by emailing .

Subcategories

1 2 1